

Zydus to present EVIDENCES IV clinical trial results of Saroglitazar Magnesium in NAFLD and NASH at AASLD's The Liver Meeting®

Ahmedabad, India, October 23, 2019

- **Late-breaker abstract L010 has been selected for oral presentation at The Liver Meeting® 2019 in Boston**
- **Statistically significant 44.39 % reduction in ALT observed with Saroglitazar Magnesium treated patients**
- **Statistically significant reduction in hepatic fat content as measured by MRI-PDFF observed in patients treated with Saroglitazar Magnesium**

Zydus Cadila, an innovation-driven, global pharmaceutical company, announced that the data of its EVIDENCES IV clinical trial of Saroglitazar Magnesium, will be presented at The Liver Meeting® 2019, the annual meeting of the American Association for the Study of Liver Diseases (AASLD), being held in Boston, Massachusetts, USA from 8th to 12th November, 2019.

Earlier Zydus had reported that the EVIDENCES IV clinical trial had achieved the primary end-points in patients with NAFLD and NASH.

Speaking on the development, Mr. Pankaj R. Patel, Chairman, Zydus Group said, “We are pleased that the data of Saroglitazar Mg trial in NASH has been selected for oral presentation at the AASLD's The Liver Meeting. NASH represents a significant public health concern for which there is currently no approved drug therapy, and we are committed to developing this novel molecule for millions of patients suffering from NASH”.

Title: “A PHASE 2, PROSPECTIVE, MULTICENTER, DOUBLE-BLIND, RANDOMIZED STUDY OF SAROGLITAZAR MAGNESIUM 1 MG, 2 MG OR 4 MG VERSUS PLACEBO IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE AND/OR NONALCOHOLIC STEATOHEPATITIS (EVIDENCES IV)”

Session Title : Late-Breaking Abstract Oral Session II
Presentation Type : Oral, Parallel Session
Session Date and Time : Tuesday, November 12, 2019, 8:00 AM
Presentation Time : 8:45 AM
Location : Auditorium, Hynes Convention Center

About NASH

NASH is the area of significant unmet medical need, with an estimated 6.5 million adults in the United States and five major European countries having advanced NASH. NASH is a progressive disease of the liver. Starting with fat accumulation in liver, this condition can progress to cirrhosis and liver failure. NASH ranks as one of the major causes of cirrhosis in America, behind hepatitis C and alcoholic liver disease. Liver transplantation is the only option for managing advanced cirrhosis with liver failure. There are currently no treatments approved by the U.S. Food and Drug Administration (USFDA) for treatment of NASH.

About Saroglitazar Magnesium

Saroglitazar Magnesium is an investigational molecule in USA, undergoing clinical evaluation for treatment of liver diseases like NAFLD with polycystic ovary syndrome (PCOS), Nonalcoholic Steatohepatitis (NASH) and Primary Biliary Cholangitis (PBC). Nonclinical studies have demonstrated that Saroglitazar, because of its unique mechanism of engaging PPAR alpha and PPAR gamma, favorably affects all components of NASH including steatosis, ballooning, inflammation and fibrosis.

About Zydus

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies, including small molecule drugs, biologic therapeutics and vaccines. The group employs over 24,000 people worldwide, including 1400 scientists engaged in R & D, and is dedicated to creating healthier communities globally. www.zyduscadila.com
